VIOLIN: Vaccine Investigation and Online Information Network

Vaccine Detail

GD2-CAR

Vaccine Information

Vaccine Name: GD2-CAR
Target Pathogen: Cancer
Target Disease: Cancer
Type: Other
Status: Clinical trial
Host Species for Licensed Use: None
Antigen: GD2 (NCT02107963)
Immunization Route: Other
Description: T cells are genetically engineered to express anti-GD2 Chimeric Antigen Receptor to treat patients with children and young adults with GD2+ solid tumors, including neuroblastoma. The T cells may have an antitumor effect. They can be used in combination with AP1903 and Cyclophosphamide. (NCT02107963) There are increased CXCR3- classical monocytes in patients as CAR-T numbers waned. (Kaczanowska et al., 2024)

Host Response

References

Kaczanowska et al., 2024: Kaczanowska S, Murty T, Alimadadi A, Contreras CF, Duault C, Subrahmanyam PB, Reynolds W, Gutierrez NA, Baskar R, Wu CJ, Michor F, Altreuter J, Liu Y, Jhaveri A, Duong V, Anbunathan H, Ong C, Zhang H, Moravec R, Yu J, Biswas R, Van Nostrand S, Lindsay J, Pichavant M, Sotillo E, Bernstein D, Carbonell A, Derdak J, Klicka-Skeels J, Segal JE, Dombi E, Harmon SA, Turkbey B, Sahaf B, Bendall S, Maecker H, Highfill SL, Stroncek D, Glod J, Merchant M, Hedrick CC, Mackall CL, Ramakrishna S, Kaplan RN. Immune determinants of CAR-T cell expansion in solid tumor patients receiving GD2 CAR-T cell therapy. Cancer cell. 2024; 42(1); 35-51.e8. [PubMed: 38134936].

NCT02107963: A Phase I Trial of T Cells Expressing an Anti-GD2 Chimeric Antigen Receptor in Children and Young Adults With GD2+ Solid Tumors [https://clinicaltrials.gov/study/NCT02107963]